1. Associations between lipid subfractions and serum myeloperoxidase levels in untreated hyperlipidemic patients. (September 2016) Authors: Szentpéteri, A.; Lőrincz, H.; Zsíros, N.; Varga, V.E.; Seres, I.; Katkó, M.; Fülöp, P.; Paragh, G.; Harangi, M. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cerebrotendinous xanthomatosis with the c.379C>T (p.R127W) mutation in the CYP27A1 gene associated with premature age‐associated limbic tauopathy. Issue 3 (April 2014) Authors: Kapás, I.; Katkó, M.; Harangi, M.; Paragh, G.; Balogh, I.; Kóczi, Z.; Regelsberger, G.; Molnár, M. J.; Kovacs, G. G. Journal: Neuropathology & applied neurobiology Issue: Volume 40:Issue 3(2014) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Characterization of fetuin-A levels in patients with autoimmune thyroid disease. (August 2022) Authors: Lengyel, I.; Halmi, S.; Lőrincz, H.; Bak-Csiha, S.; Katkó, M.; Harangi, M.; Nagy, E.V.; Paragh, G.; Bodor, M.; Berta, E. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Importance of serum cholestanol measurement by gas chromatography-mass spectrometry in a rare congenital neurodegenerative disease: Cerebrotendinous xanthomatosis. Issue 1 (July 2015) Authors: Varga, V.E.; Katkó, M.; Harangi, J.; Seres, I.; Paragh, G.; Harangi, M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Myeloperoxidase and human paraoxonase-1 correlates with vascular biomarkers in untreated hyperlipidemic patients. Issue 1 (July 2015) Authors: Paragh, G.; Zsíros, N.; Varga, V.E.; Szentpéteri, A.; Lorincz, H.; Katkó, M.; Seres, I.; Fülöp, P.; Harangi, M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Plasminogen activator inhibitor-1 level associated with the components of metabolic syndrome in a 4G/5G polymorphism dependent manner. (August 2022) Authors: Lőrincz, H.; Galgóczy, E.; Katkó, M.; Ratku, B.; Ötvös, T.; Harangi, M.; Paragh, G.; Szabó, Z.; Somodi, S. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Strong correlations between serum fibroblast growth factor 21 level and lipid parameters in patients with autoimmune thyroiditis. (August 2021) Authors: Berta, E.; Bodor, M.; Halmi, S.; Lengyel, I.; Diószegi, Á.; Katkó, M.; Seres, I.; Nagy, E.V.; Paragh, G.; Harangi, M. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The effect of iatrogenic hypothyroidism on lipoprotein subfractions and serum paraoxonase activity in patients with differentiated thyroid cancer. (August 2022) Authors: Katkó, M.; Gazdag, A.; Harangi, M.; Szentpéteri, A.; Galgóczi, E.; Erdei, A.; Berta, E.; Bodor, M.; Bhattoa, H.P.; Nagy, E.V. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗